Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Breast Neoplasms, Ovarian Neoplasms, Colonic Neoplasms, Prostatic Neoplasms, Uterine Cervical Neoplasms, Leukemia, Lymphoma, Non-Hodgkin
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
992 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone
Interventions
68Ga PSMA-11 injection, Positron Emission Tomography/Computed Tomography
Drug · Procedure
Lead sponsor
Dana Mathews
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Prostate Adenocarcinoma
Interventions
Niraparib Pill
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Prostatic Neoplasms
Interventions
RTVP-1 Gene
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Houston, Texas
Conditions
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
177Lu-BetaBart
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska
Conditions
Neoplasms
Interventions
GSK2636771, Enzalutamide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Completed Phase 3 Interventional Results available

68Ga-PSMA-11 PET in Patients With Prostate Cancer

NCT05197257
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Ga-PSMA-11
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Conditions
Prostate Cancer
Interventions
Grape Seed Extract
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Fort Collins, Colorado
Completed Not applicable Interventional Results available

Optimizing Veteran-Centered Prostate Cancer Survivorship Care

NCT01900561
Conditions
Prostate Cancer
Interventions
Interactive Voice Response Symptom Management, Tailored Newsletters
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 80 Years · Male only
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Cleveland, Ohio + 1 more
Conditions
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
Interventions
LY3410738, Gemcitabine, Cisplatin, Durvalumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Orange, California + 3 more
Conditions
Prostate Cancer, Osteoporosis, Fractures
Interventions
Toremifene Citrate
Drug
Lead sponsor
GTx
Industry
Eligibility
50 Years and older · Male only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
136
States / cities
Homewood, Alabama • Mobile, Alabama • Little Rock, Arkansas + 117 more
Conditions
Prostate Cancer, Localized Prostate Cancer
Interventions
[18F] DIHYDRO-TESTOSTERONE, PET scan, MRI, Blood draw
Drug · Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 79 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Prostate-specific Membrane Antigen Positive Tumors, Prostate Cancer, Breast Cancer, Lung Cancer
Interventions
[Ga-68]PSMA PET/MR
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma
Interventions
(R)-9bMS
Drug
Lead sponsor
TechnoGenesys, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Prostate Cancer
Interventions
Enzalutamide, Bicalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
109
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 76 more
Conditions
Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer
Interventions
Pasireotide, Everolimus, Laboratory biomarker analysis
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
New Haven, Connecticut • Philadelphia, Pennsylvania
Conditions
Lung Cancer, Pleural Cancer, Prostate Cancer
Interventions
diagnostic
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
2
States / cities
Orange, California
Conditions
Prostate Cancer
Interventions
Prostate Ablation
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
22 Years and older · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Hyde Park, Illinois • Cincinnati, Ohio
Conditions
Prostate Cancer
Interventions
225Ac-J591, 177Lu-PSMA-617, 68Ga-PSMA-11, 177Lu-PSMA-I&T
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Conditions
Metastatic Prostate Cancer
Interventions
Enzalutamide, Niraparib
Drug
Lead sponsor
Paul Mathew, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
chemotherapy, tributyrin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2003
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms
Interventions
LY4257496, Standard of Care Anticancer Therapies, LY4257529
Drug · Diagnostic Test
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
16
States / cities
Duarte, California • Santa Monica, California • Stanford, California + 11 more
Conditions
Prostate Cancer
Interventions
Ferumoxytol
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland